Modality
mRNA
MOA
ALKi
Target
APOC3
Pathway
Angiogenesis
AML
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ Nov 2031
Phase 1Current
NCT03105978
2,903 pts·AML
2017-04→2031-10·Terminated
NCT05751024
2,921 pts·AML
2017-09→2031-11·Completed
5,824 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-10-215.6y awayInterim· AML
2031-11-015.6y awayInterim· AML
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Termina…
P1
Complet…
Catalysts
Interim
2031-10-21 · 5.6y away
AML
Interim
2031-11-01 · 5.6y away
AML
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03105978 | Phase 1 | AML | Terminated | 2903 | PANSS |
| NCT05751024 | Phase 1 | AML | Completed | 2921 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |